showed that the maximum loading capacity of the liposomes was around 1.5% of 23 curcumin, although the loading capacity of the hybrid microencapsulation structures 24 increased with the curcumin content by incorporation of curcumin microcrystals upon 25 electrospraying. Microencapsulation of curcumin within the proposed hybrid structures 26 significantly increased its bioaccessibility (~1.7-fold) compared to the free compound, 27 and could successfully stabilize it against degradation in PBS (pH = 7.4). The proposed 28 approach thus proved to be a promising alternative to produce powder-like functional 29 
Production of hybrid microencapsulation structures by electrospraying 148
The previous formulations were processed using a homemade electrospinning/ 149 electrospraying apparatus assembled in-house. The dispersions were pumped with a 150 digitally controlled syringe pump model KDS-100 (KDScientific, USA) at a flow-rate 151 of 0.15 mL/h through a needle with an inner diameter of 0.84 mm. Processed samples 152 were collected on a grounded copper plate covered with aluminium foil which was 153 placed at a distance of 10 cm from the tip of the needle in a horizontal configuration. 
Entrapment efficiency within the liposomes 172
The liposome dispersions were centrifuged at 100×g and 4 °C for 5 min using a Heal 173
Force Neofuge 23R centrifuge (Thanes Science, Thailand). These conditions were 174 optimized in preliminary trials to precipitate the non-encapsulated crystals of curcumin 175
and not the liposomes. The supernatant was diluted 4-fold with ethanol, dissolving the9 liposomes and curcumin. Polarized light microscopy images were taken using a digital microscopy system 186 (Nikon, Multizoom AZ100, Japan) equipped with a polarized light source (Nikon, C-187 FI115 Fiber Illuminator, Japan) and a digital camera head (Nikon, DS-Ri1, Japan). 188 The amount curcumin released during digestion was estimated after centrifugation of 226 the digestas. The supernatants were freeze-dried, re-suspended in water and extracted 227 with 70 % acetonitrile before HPLC-MS analysis. Eluent A was water slightly acidified 228 with 0.005% acetic acid, and eluent B acetonitrile with 0.005% acetic acid, working in 229 isocratic mode at 70% of eluent B. The LC system used for this analysis was an 230 Acquity® TQD system from Waters. Separation of curcumin was performed using an 231 Acquity UPLC C18 Kinetex (Phenomenex, 100 mm x 2.1 mm, 1.7 μm particle size) 232 LC-column. The flow rate was set to 0.4 mL/min. The injection volume was 5 µl. The 233 mass spectrometer was equipped with a Z-spray electrospray ionization source and 234 spectra were acquired in positive ionization multiple reaction monitoring (MRM) mode 235 with interchannel delay of 0.16 s. The bioaccessibility was estimated according to Eq. 5 After mixing with the protein dispersion, the mixture was electrosprayed. 328 Table 1 Table 2 . 350 The results showed that the encapsulation efficiency decreased with the amount of 351 curcumin added to the lipids solutions. However, no significant differences were 352 observed in the loading capacity of the samples, regardless of the initial curcumin 353 concentration. Therefore, it was concluded that a maximum curcumin loading of about 354 Results showed that the bioaccessibility of pure curcumin was very low, as expected. 436
Microencapsulation of the compound within the proposed hybrid structures, however, 437 significantly increased its bioaccessibility (~1.7-fold), regardless of the curcumin 438 content in the capsules. It is worth noting that, although the loading capacity of the 439 hybrid microcapsules was different for each sample, the loading capacity of the 440 precursor liposomes was not statistically different (cf. Table 2 ) and thus the amount of 441 'liposomal curcumin' is expected to be similar in all capsules subjected to digestion. 442 Accordingly, no statistically significant differences were observed among the 443 microencapsulated samples. In this sense, incorporation of theoretical curcumin 444 contents greater than 1% in the precursor liposomes was considered impractical, as it 445 did not further improve the bioaccessibility of curcumin while it led to lower 446 encapsulation efficiencies. 447 448
Protective effect of microencapsulation 449
In order to assess whether the microencapsulation of curcumin within the proposed 450 system effectively stabilize the bioactive ingredient, the free and encapsulated 451 compound were dissolved/dispersed in PBS (pH=7.4) medium in which curcumin has 452 been described to be very unstable undergoing rapid hydrolytic degradation (Changguo 
